Sodium Enoxaparine

Phase 3Small molecule

BBiocad

Sodium Enoxaparine is one of 27 small molecule programs targeting Deep Vein Thrombosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Deep Vein ThrombosisActive, not recruiting

Deep Vein ThrombosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Deep Vein Thrombosis

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

6 2

Lovenox

Sanofi

Approved

5 3

Xarelto

WWim Janssens

Approved

12 4

Innohep

Alnylam Pharmaceuticals

Approved

1 5

Savaysa

Daiichi Sankyo

Approved

—6

Heparin Sodium

BBaxter Healthcare Corporation

Approved

1 7

Angiomax

BBaxter Healthcare Corporation

Approved

—8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Approved

1 9

Coumadin

AAbbott

Phase 3

5 10

Diosmin

TTanta University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Deep Vein Thrombosis1 trial

A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries

Completed·BBiocad·Phase 3·NCT02368314·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sodium Enoxaparine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Enoxaparine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Enoxaparine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBiocad

Sodium Enoxaparine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Deep Vein Thrombosis1 trial

References

Drug Info

Quick Facts

Related News